Anavex Life Sciences’ (AVXL) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note released on Monday,Benzinga reports. They currently have a $46.00 price target on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Anavex Life Sciences in a research note on Wednesday, November 27th.

Anavex Life Sciences Trading Down 2.8 %

Shares of NASDAQ:AVXL opened at $10.87 on Monday. The company has a market cap of $921.73 million, a PE ratio of -21.74 and a beta of 0.73. The company’s 50 day moving average is $8.02 and its two-hundred day moving average is $6.32. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $12.48.

Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.03. As a group, equities research analysts expect that Anavex Life Sciences will post -0.55 EPS for the current year.

Institutional Investors Weigh In On Anavex Life Sciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in shares of Anavex Life Sciences during the second quarter worth about $57,000. Orion Capital Management LLC increased its position in Anavex Life Sciences by 666.7% during the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after buying an additional 10,000 shares during the period. PVG Asset Management Corp purchased a new stake in Anavex Life Sciences in the third quarter valued at approximately $74,000. Atria Investments Inc acquired a new stake in shares of Anavex Life Sciences in the third quarter valued at approximately $76,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Anavex Life Sciences by 97.0% in the third quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock valued at $86,000 after acquiring an additional 7,421 shares during the period. 31.55% of the stock is owned by hedge funds and other institutional investors.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.